



04.19.21 | INVESTMENT MANAGEMENT

2021 Outlook Theme #1, 3/31/21 Update: Diverging then Converging Headlines

Benjamin B. Wallace, CFA – Portfolio Manager, Research Director

Our first 2021 Theme was focused on the broadly predictable trends of the Covid-19 virus, and vaccines “*...a process we refer to as Diverging, then Converging Headlines. The vaccine and virus data first are on deviating paths, then both moving towards a favorable outcome in the second half of 2021.*

Q1'21 will see the vaccine timeline continue to progress in a positive direction, while the virus news remains negative. This will likely be the most challenging period, with the virus trend at its worst and the vaccine trend most likely to produce stories of delays and other start up mishaps. During Q2'21, the virus data should begin to turn and, hopefully, put both the vaccine and virus timelines on a converging course.

The markets will be locked onto this convergence, expected in late Q2'21, as opposed to the potential deceleration in economic data in late Q4'20 and into Q1'21. As long as neither trend shifts significantly enough to take the markets focus off that end of Q2'21 target, the Q1 headlines will be seen as merely noise. Since markets are forward looking, as 2021 progresses their focus will shift to the second half and where economic activity will go once the trends begin to converge.

The framework was broadly correct. The potential fault is one we should have anticipated better: the speed of this divergence, then convergence. The pattern of good vaccine data converging with improving virus trends went extremely fast, just as with most other features of this cycle. While headlines from the cresting second wave were prominent in January, by February it switched to the rising production of vaccines feeding the growing inoculated population, plus a sharp drop in Covid-19 cases, hospitalizations, and deaths. In short, what we laid out as a Q1 divergence of vaccine progress but poor virus trends, followed by a Q2 convergence as virus and vaccine trends both turned positive, instead ran through the full process just in Q1.

The only caveat is that this also accelerated the market trends. Rates rose quickly. Value significantly outperformed Growth. Industries that stand to recover traded higher on recovery optimism versus short term disruptions. Thus, the expected shift in the market's focus to the strong, post vaccination recovery, may start to take hold in Q2, as opposed to Q3 and Q4, under our slower timeline.

With this optimism, there is also room for disappointment to creep in. Even though Q2'21 will see the near full vaccinating

of the US adult population, this could be tempered by the combination of more transmissible variants and re-opening economies spurring more cases in the yet to be vaccinated population. The likely feature will be stories of increased cases in younger patients, as this less vaccinated and more active group spurs circulation. The positive feature should be considerably lower severe outcomes (hospitalizations, mortality) due to the already high levels of vaccinations in vulnerable populations.

Globally, vaccine rollouts are not going as fast as in the US, but they should start to pick up pace. The EU, for example, is targeting 50% of its population in July. Overall, if it's the pandemic that has caused the recession, and the recovery from the pandemic seems to be accelerating towards normal, then we need to start thinking harder about how markets will price "normal".

Please remember that past performance may not be indicative of future results. Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product (including the investments and/or investment strategies recommended or undertaken by Grimes & Company, Inc. ("Grimes")), or any non-investment related content, made reference to directly or indirectly in this commentary will be profitable, equal any corresponding indicated historical performance level(s), be suitable for your portfolio or individual situation, or prove successful. Due to various factors, including changing market conditions and/or applicable laws, the content may no longer be reflective of current opinions or positions. Moreover, you should not assume that any discussion or information contained in this commentary serves as the receipt of, or as a substitute for, personalized investment advice from Grimes. Please remember to contact Grimes, in writing, if there are any changes in your personal/financial situation or investment objectives for the purpose of reviewing / evaluating / revising our previous recommendations and/or services, or if you would like to impose, add, or to modify any reasonable restrictions to our investment advisory services. Unless, and until, you notify us, in writing, to the contrary, we shall continue to provide services as we do currently. Grimes is neither a law firm, nor a certified public accounting firm, and no portion of its services should be construed as legal or accounting advice. A copy of our current written disclosure Brochure discussing our advisory services and fees is available upon request. Please advise us if you have not been receiving account statements (at least quarterly) from the account custodian.

Historical performance results for investment indices, benchmarks, and/or categories have been provided for general informational/comparison purposes only, and generally do not reflect the deduction of transaction and/or custodial charges, the deduction of an investment management fee, nor the impact of taxes, the incurrence of which would have the effect of decreasing historical performance results. It should not be assumed that your Grimes account holdings correspond directly to any comparative indices or categories. **Please Also Note:** (1) performance results do not reflect the impact of taxes; (2) comparative benchmarks/indices may be more or less volatile than your Grimes accounts; and, (3) a description of each comparative benchmark/index is available upon request.

The information contained herein is based upon sources believed to be true and accurate. Sources include: *Factset Research Systems Inc.*, Bureau of Economic Analysis, Bureau of Labor Statistics, Congressional Budget Office, Board of Governors of Federal Reserve System, Fred: Federal Reserve Bank of St. Louis Economic Research, U.S. Department of the Treasury

-The Standard & Poor's 500 is a market capitalization weighted index of 500 widely held domestic stocks often used as a proxy for the U.S. stock market. The Standard & Poor's 400 is a market capitalization weighted index of 400 mid cap domestic stocks. The Standard & Poor's 600 is a market capitalization weighted index of 600 small cap domestic stocks.

-The NASDAQ Composite Index measures the performance of all issues listed in the NASDAQ stock market, except for rights, warrants, units, and convertible debentures.

-The MSCI EAFE Index (Europe, Australasia, Far East) is a free float-adjusted market capitalization index that is designed to measure the equity market performance of developed markets, excluding the US & Canada. The MSCI Emerging Markets Index is a free float-adjusted market capitalization index that is designed to measure equity market performance of 21 emerging markets. The MSCI All Country World Index is a free float adjusted market capitalization index designed to measure the performance of large and mid and cap stocks in 23 developed markets and 24 emerging markets. With over 2,800 constituents it represents over 85% of the global equity market.

-The Barclays Aggregate Index represents the total return performance (price change and income) of the US bond market, including Government, Agency, Mortgage and Corporate debt.

-The BofA Merrill Lynch Investment Grade and High Yield Indices are compiled by Bank of America / Merrill Lynch from the TRACE bond pricing service and intended to represent the total return performance (price change and income) of investment grade and high yield bonds.

-The S&P/LSTA U.S. Leveraged Loan 100 is designed to reflect the largest facilities in the leveraged loan market. It mirrors the market-weighted performance of the largest institutional leveraged loans based upon market weightings, spreads and interest payments.

-The S&P Municipal Bond Index is a broad, comprehensive, market value-weighted index. The S&P Municipal Bond Index constituents undergo a monthly review and rebalancing, in order to ensure that the Index remains current, while avoiding excessive turnover. The Index is rules based, although the Index Committee reserves the right to exercise discretion, when necessary.

-The BofA Merrill Lynch US Emerging Markets External Sovereign Index tracks the performance of US dollar emerging markets sovereign debt publicly issued in the US and eurobond markets.

-The HFRI Fund of Funds index is compiled by the Hedge Funds Research Institute and is intended to represent the total return performance of the entire hedge fund universe.